Male Breast Cancer.
Breast cancer is a rare disease in men representing nearly 1% of the total breast cancer cases worldwide. Due to the low incidence, there are no randomized clinical studies giving information on the optimal diagnostics and therapy for male breast cancer patients. Therefore, treatment recommendations are derived from established guidelines for breast cancer in women. However, the lack of awareness of this disease leads to its detection at a later stage in men associated with a worse prognostic outcome. The gender-specific differences in breast cancer are among others related to the differing genetic and hormonal environment and the anatomic constitution in men. For example, males have a much higher percentage of hormone receptor-positive tumors but a significantly lower fraction of carcinomas overexpressing HER2. This review focuses on epidemiology, pathogenesis, and clinical findings of male breast cancer, and discusses current findings available to treat this disease. To optimize disease outcome and tolerability of treatment, these data should be considered to improve the therapeutic index of male breast cancer patients.
Rudlowski
Christian
C
Department of Gynecology and Obstetrics, University Hospital, Bonn, Germany.
Am J Clin Oncol. 1987 Feb;10(1):55-60
3825994
Br J Cancer. 1973 Dec;28(6):552-61
4783156
Cancer. 2001 Jan 15;91(2):319-23
11180077
Radiol Technol. 1994 May-Jun;65(5):331-3
8058916
Surgery. 1999 Oct;126(4):775-80; discussion 780-1
10520928
Am Surg. 2000 May;66(5):502-11
10824754
Br J Nurs. 2001 Aug 9-Sep 12;10(15):975-81
11923732
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):20-6
15668471
Br J Cancer. 1992 Feb;65(2):252-4
1739625
Am J Hum Genet. 1998 Mar;62(3):676-89
9497246
Cancer. 2004 Jul 1;101(1):51-7
15221988
Am J Surg. 1997 Mar;173(3):185-8
9124623
Int J Cancer. 2004 Jan 20;108(3):479-80
14648719
Ann Surg. 1992 May;215(5):451-7; discussion 457-9
1319699
Cancer Causes Control. 1998 May;9(3):269-75
9684707
Breast Cancer Res Treat. 2004 Apr;84(3):215-23
15026619
Eur J Surg Oncol. 2004 Jun;30(5):480-3
15135473
J Clin Oncol. 2008 Feb 10;26(5):736-44
18258981
J Natl Cancer Inst. 1991 Jun 19;83(12):849-54
2061945
Radiographics. 2006 Jul-Aug;26(4):993-1006
16844928
Br J Cancer. 2003 Mar 24;88(6):933-6
12644832
Eur J Cancer. 1997 Jan;33(1):35-8
9071896
Radiother Oncol. 1999 Oct;53(1):29-35
10624850
Cancer. 1998 Aug 1;83(3):498-509
9690543
Nat Clin Pract Oncol. 2006 Aug;3(8):428-37
16894388
Surg Oncol. 1993 Dec;2(6):325-33
8130939
Radiol Technol. 1997 Sep-Oct;69(1):17-28; quiz 29-36
9323763
Breast Cancer Res. 2004;6(1):R18-23
14680496
J Clin Oncol. 2006 Jul 20;24(21):e42-3
16849742
Cancer. 2005 Dec 1;104(11):2359-64
16270318
Breast Cancer Res Treat. 2007 May;103(1):11-21
17033919
Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S25-30
7942610
Cancer. 1993 Jan 1;71(1):154-61
8416712
J Steroid Biochem. 1973 Sep;4(5):489-501
4782681
Strahlenther Onkol. 1996 Jul;172(7):369-75
8693403
Tumori. 1990 Dec 31;76(6):555-8
2284691
Radiology. 2006 Feb;238(2):438-45
16371581
Ann Surg. 1978 Jul;188(1):60-5
208472
Cancer Treat Rev. 2006 Apr;32(2):101-5
16472925
Cancer. 1999 Feb 1;85(3):629-39
10091736
Eur J Cancer. 1995 Nov;31A(12):1960-4
8562148
Radiographics. 1999 May-Jun;19(3):559-68
10336188
Breast Cancer Res. 2002;4(1):R2
11879560
Breast Cancer Res Treat. 2003 Jan;77(1):9-14
12602900
Int J Cancer. 1993 Feb 20;53(4):538-49
8436428
Int J Cancer. 1992 Apr 22;51(1):62-6
1563846
Radiother Oncol. 2002 Nov;65(2):99-103
12443805
N Engl J Med. 2001 Sep 27;345(13):997-8
11575298
Eur J Surg Oncol. 1998 Dec;24(6):548-52
9870732
Oncologist. 2005 Aug;10(7):471-9
16079314
Tumori. 2005 Mar-Apr;91(2):151-5
15948543
Lancet. 2006 Feb 18;367(9510):595-604
16488803
J Surg Oncol. 2004 May 1;86(2):74-7
15112248